WELCOME TO

Specialist Communications for Life Sciences
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.

Our
Services
Focused on supporting life science companies to raise their profile, build corporate value, and generate interest, the services we provide include:
PR & Media
- Press releases
- Article writing and placement
- Media interviews
- Messaging
- Copy writing
- Social media
- Media training
- Events
Marketing
- Conference, event and trade show support
- Marketing literature
- Market research
- Campaign development
- Advertising
- Sponsorship
- Product launches
Design & Branding
- Website design and development
- Print collateral development
- Identity and logo creation
- Brand strategy
- Presentation development
- Video production
Investor Relations
- Business plan development
- Presentation development
- PR targeting the life science trade press read by investors

The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
SLAS Europe 2026
-
BioSeed Summer 2026
-
Cambridge Wide Open Week 2026
-
Milner Therapeutics Symposium 2026
OutSee selected for Discovery Award from Longitude Prize on ALS to accelerate AI-based target discovery
Funding to identify novel targets for ALS treatment using OutSee’s ‘genomics first’ target discovery platform, Nomaly Provides access to world’s largest and most comprehensive ALS patient dataset Part of £7.5M [...]
Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis
UK NHS grants HRA/REC approval for PEMP study with Peterborough and Cambridge hospitals Clinical observational study investigating underlying biology of endometriosis aims to uncover causal mechanisms and new druggable targets [...]
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkers The focus of these efforts will be on the quantitative assessment [...]






















